Medikamentöse Therapie der Endometriose

Stefanie Burghaus
In: Die Gynäkologie · 2026 · doi:10.1007/s00129-026-05522-7 · W7167493993
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-07+body, 2026-07-08 ⓘ

This review details drug therapy for endometriosis, recommending individualized, symptom-oriented treatment with progestins and GnRH antagonists as first-line options, and GnRH agonists for refractory cases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-08 ⓘ

The paper reviews medication-based treatment for endometriosis, focusing on symptom control—especially pain—and suppression of disease activity, based on the current S2k guideline and summarized literature rather than new patient data. It reports that individualized, symptom- and context-oriented therapy should consider the patient’s situation, desire for children, and side-effect profiles, with progestins and oral GnRH antagonists (after prior surgery) as first-line options. GnRH agonists are described as effective for therapy-refractory cases or specific situations but requiring careful side-effect management. This paper is centrally about endometriosis — it outlines guideline-based principles and first-line pharmacologic options for controlling endometriosis-associated pain and disease activity.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (13)

Source provenance

openalex
last seen: 2026-07-10T06:00:46.527841+00:00
License: CC0 · commercial use OK